title: Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation.
abstract: Tumor recurrence remains a major problem for patients with cancer, even after initial beneficial responses to standard-of-care chemotherapeutic agents. With the recent advances in immunotherapy strategies, there is growing interest in synergistically combining immunotherapy with conventional chemotherapy to achieve durable antitumor effects. In some cases, chemotherapy-induced myeloid suppressor cells represent a critical obstacle to achieving this goal.
authors.affiliation: Cancer Immunotherapy; Inflammation and Tolerance Program ; Cancer Center; Georgia Regents University (GRU) ; Augusta, GA, USA.
authors.forename: Zhi-Chun
authors.initials: ZC
authors.lastname: Ding
authors.affiliation: Cancer Immunotherapy; Inflammation and Tolerance Program ; Cancer Center; Georgia Regents University (GRU) ; Augusta, GA, USA.
authors.forename: David H
authors.initials: DH
authors.lastname: Munn
authors.affiliation: Cancer Immunotherapy; Inflammation and Tolerance Program ; Cancer Center; Georgia Regents University (GRU) ; Augusta, GA, USA.
authors.forename: Gang
authors.initials: G
authors.lastname: Zhou
keywords: Abbreviations: CTX; CTX-induced myeloid-derived suppressor cells; MDSC; PD-1; chemotherapy; cyclophosphamide; CTX-MDSCs; immunotherapy; inflammation; monocytic myeloid-derived suppressor cells; myeloid-derived suppressor cells; myeloid-derived suppressor cells; MO-MDSCs